Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Stock Has Consensus Price Target of $46.08

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has been assigned a consensus recommendation of “Moderate Buy” from the fourteen brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $46.08.

Several brokerages have issued reports on TEVA. UBS Group boosted their target price on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a research report on Friday, September 4th. Wall Street Zen cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Zacks Research downgraded Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. Oppenheimer lifted their price objective on shares of Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the stock an “outperform” rating in a research report on Friday, October 9th. Finally, Barclays upped their target price on Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the company an “overweight” rating in a research report on Thursday, October 15th.

Teva Pharmaceutical Industries Stock Down 2.0%

Shares of NYSE:TEVA opened at $39.39 on Friday. The company has a market cap of $45.90 billion, a price-to-earnings ratio of 65.65, a PEG ratio of 3.66 and a beta of 0.89. Teva Pharmaceutical Industries has a 12 month low of $18.88 and a 12 month high of $42.02. The company has a 50-day moving average price of $38.67 and a 200 day moving average price of $35.27. The company has a current ratio of 0.88, a quick ratio of 0.67 and a debt-to-equity ratio of 1.56.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. The firm had revenue of $4.14 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 32.64% and a net margin of 4.08%. As a group, equities research analysts predict that Teva Pharmaceutical Industries will post 2.00 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Brian Savage sold 7,342 shares of the firm’s stock in a transaction on Friday, September 18th. The stock was sold at an average price of $38.85, for a total value of $285,236.70. Following the completion of the transaction, the insider owned 8,500 shares in the company, valued at $330,225. This trade represents a 46.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Roberto Mignone sold 367,600 shares of the firm’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $39.06, for a total value of $14,358,456.00. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 374,959 shares of company stock valued at $14,644,285 in the last 90 days. 0.54% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of TEVA. Signaturefd LLC raised its position in shares of Teva Pharmaceutical Industries by 9.6% in the third quarter. Signaturefd LLC now owns 17,329 shares of the company’s stock worth $686,000 after acquiring an additional 1,520 shares during the period. Evergreen Capital Management LLC lifted its position in shares of Teva Pharmaceutical Industries by 66.7% in the third quarter. Evergreen Capital Management LLC now owns 17,779 shares of the company’s stock valued at $704,000 after acquiring an additional 7,111 shares in the last quarter. Winthrop Advisory Group LLC purchased a new position in Teva Pharmaceutical Industries in the 3rd quarter valued at $206,000. Wedbush Securities Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 5.0% in the third quarter. Wedbush Securities Inc. now owns 22,435 shares of the company’s stock worth $888,000 after buying an additional 1,062 shares in the last quarter. Finally, Yousif Capital Management LLC lifted its stake in Teva Pharmaceutical Industries by 10.1% in the 3rd quarter. Yousif Capital Management LLC now owns 46,708 shares of the company’s stock worth $1,850,000 after purchasing an additional 4,285 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company is one of the world’s largest producers of generic medicines and develops, manufactures and distributes prescription products across a broad range of therapeutic areas.

Teva’s portfolio includes generic medicines, specialty pharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products. Its specialty medicines include treatments for neurological and movement disorders, respiratory conditions, migraine and other chronic diseases.